Literature DB >> 30354326

Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort.

Akinyemi Oni-Orisan1,2, Thomas J Hoffmann2,3, Dilrini Ranatunga4, Marisa W Medina5, Eric Jorgenson4, Catherine Schaefer4, Ronald M Krauss6,5, Carlos Iribarren3,4, Neil Risch2,3,4.   

Abstract

BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) response to statin therapy has not been fully elucidated in real-world populations. The primary objective of this study was to characterize statin LDL-C dose-response and its heritability in a large, multiethnic population of statin users.
METHODS: We determined the effect of statin dosing on lipid measures utilizing electronic health records in 33 139 statin users from the Kaiser Permanente GERA cohort (Genetic Epidemiology Research on Adult Health and Aging). The relationship between statin defined daily dose and lipid parameter response (percent change) was determined.
RESULTS: Defined daily dose and LDL-C response was associated in a log-linear relationship (β, -6.17; SE, 0.09; P<10-300) which remained significant after adjusting for prespecified covariates (adjusted β, -5.59; SE, 0.12; P<10-300). Statin type, sex, age, smoking status, diabetes mellitus, and East Asian race/ethnicity were significant independent predictors of statin-induced changes in LDL-C. Based on a variance-component method within the subset of statin users who had at least 1 first-degree relative who was also a statin user (n=1036), heritability of statin LDL-C response was estimated at 11.7% (SE, 8.6%; P=0.087).
CONCLUSIONS: Using electronic health record data, we observed a statin LDL-C dose-response consistent with the rule of 6% from prior clinical trial data. Clinical and demographic predictors of statin LDL-C response exhibited highly significant but modest effects. Finally, statin-induced changes in LDL-C were not found to be strongly inherited. Ultimately, these findings demonstrate (1) the utility of electronic health records as a reliable source to generate robust phenotypes for pharmacogenomic research and (2) the potential role of statin precision medicine in lipid management.

Entities:  

Keywords:  Hydroxymethylglutaryl-CoA Reductase Inhibitors; cholesterol, LDL; electronic health record; phenotype; precision medicine

Mesh:

Substances:

Year:  2018        PMID: 30354326      PMCID: PMC6214660          DOI: 10.1161/CIRCGEN.117.002043

Source DB:  PubMed          Journal:  Circ Genom Precis Med        ISSN: 2574-8300


  34 in total

Review 1.  Safety and efficacy of statins in Asians.

Authors:  James K Liao
Journal:  Am J Cardiol       Date:  2006-12-15       Impact factor: 2.778

2.  Facilitating pharmacogenetic studies using electronic health records and natural-language processing: a case study of warfarin.

Authors:  Hua Xu; Min Jiang; Matt Oetjens; Erica A Bowton; Andrea H Ramirez; Janina M Jeff; Melissa A Basford; Jill M Pulley; James D Cowan; Xiaoming Wang; Marylyn D Ritchie; Daniel R Masys; Dan M Roden; Dana C Crawford; Joshua C Denny
Journal:  J Am Med Inform Assoc       Date:  2011 Jul-Aug       Impact factor: 4.497

3.  Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins.

Authors:  C L Shear; F A Franklin; S Stinnett; D P Hurley; R H Bradford; A N Chremos; D T Nash; A Langendorfer
Journal:  Circulation       Date:  1992-04       Impact factor: 29.690

4.  Characterization of statin dose response in electronic medical records.

Authors:  W-Q Wei; Q Feng; L Jiang; M S Waitara; O F Iwuchukwu; D M Roden; M Jiang; H Xu; R M Krauss; J I Rotter; D A Nickerson; R L Davis; R L Berg; P L Peissig; C A McCarty; R A Wilke; J C Denny
Journal:  Clin Pharmacol Ther       Date:  2013-10-04       Impact factor: 6.875

5.  LDL cholesterol response and statin adherence among high-risk patients initiating treatment.

Authors:  Suma Vupputuri; Peter J Joski; Ryan Kilpatrick; J Michael Woolley; Brandi E Robinson; Michael E Farkouh; Huifeng Yun; Monika M Safford; Paul Muntner
Journal:  Am J Manag Care       Date:  2016-03-01       Impact factor: 2.229

6.  Prevalence and Factors Associated With Statin Use Among a Nationally Representative Sample of US Adults: National Health and Nutrition Examination Survey, 2011-2012.

Authors:  Demilade Adedinsewo; Nchang Taka; Pradyumna Agasthi; Rajesh Sachdeva; George Rust; Anekwe Onwuanyi
Journal:  Clin Cardiol       Date:  2016-08-09       Impact factor: 2.882

7.  Predictors of prevalent statin use among older adults identified as statin initiators based on Medicare claims data.

Authors:  Jessica C Young; Til Stürmer; Jennifer L Lund; Michele Jonsson Funk
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-03-15       Impact factor: 2.890

8.  Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study.

Authors:  Joel A Simon; Feng Lin; Stephen B Hulley; Patricia J Blanche; David Waters; Stephen Shiboski; Jerome I Rotter; Deborah A Nickerson; Huiying Yang; Mohammed Saad; Ronald M Krauss
Journal:  Am J Cardiol       Date:  2006-01-27       Impact factor: 2.778

9.  Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients.

Authors:  Yuji Matsuzawa; Toru Kita; Hiroshi Mabuchi; Masunori Matsuzaki; Noriaki Nakaya; Shinichi Oikawa; Yasushi Saito; Jun Sasaki; Kazuaki Shimamoto; Hiroshige Itakura
Journal:  Circ J       Date:  2003-04       Impact factor: 2.993

10.  A large electronic-health-record-based genome-wide study of serum lipids.

Authors:  Thomas J Hoffmann; Elizabeth Theusch; Tanushree Haldar; Dilrini K Ranatunga; Eric Jorgenson; Marisa W Medina; Mark N Kvale; Pui-Yan Kwok; Catherine Schaefer; Ronald M Krauss; Carlos Iribarren; Neil Risch
Journal:  Nat Genet       Date:  2018-03-05       Impact factor: 38.330

View more
  8 in total

1.  Effects of statin response on cardiovascular outcomes in patients with ST-segment elevation myocardial infarction.

Authors:  Mehmet Bülent Vatan; Perihan Varım; Suret Ağaç; Hakan Erkan; Kahraman Coşansu
Journal:  Rev Assoc Med Bras (1992)       Date:  2022-08       Impact factor: 1.712

2.  Familial Resemblance in Low-Density Lipoprotein Cholesterol Response to Statins in the Danish Population.

Authors:  Giulia Corn; Marie Lund; Mark A Hlatky; Jan Wohlfahrt; Mads Melbye
Journal:  J Am Heart Assoc       Date:  2022-05-27       Impact factor: 6.106

3.  Genetic Variant ABCC1 rs45511401 Is Associated with Increased Response to Statins in Patients with Familial Hypercholesterolemia.

Authors:  Carolina Dagli-Hernandez; Jéssica Bassani Borges; Elisangela da Silva Rodrigues Marçal; Renata Caroline Costa de Freitas; Augusto Akira Mori; Rodrigo Marques Gonçalves; Andre Arpad Faludi; Victor Fernandes de Oliveira; Glaucio Monteiro Ferreira; Gisele Medeiros Bastos; Yitian Zhou; Volker M Lauschke; Alvaro Cerda; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata
Journal:  Pharmaceutics       Date:  2022-04-27       Impact factor: 6.525

Review 4.  Identifying genetic modulators of statin response using subject-derived lymphoblastoid cell lines.

Authors:  Yu-Lin Kuang; Elizabeth Theusch; Ronald M Krauss; Marisa W Medina
Journal:  Pharmacogenomics       Date:  2021-04-16       Impact factor: 2.533

5.  Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker-driven precision dosing.

Authors:  Akinyemi Oni-Orisan; Nithya Srinivas; Krina Mehta; Jesmin Lohy Das; Thu T Nguyen; Geoffrey H Tison; Scott R Bauer; Maria Burian; Ryan S Funk; Richard A Graham
Journal:  Clin Transl Sci       Date:  2021-02-12       Impact factor: 4.689

6.  Blood Lipid Responses to Diets Enriched with Cottonseed Oil Compared With Olive Oil in Adults with High Cholesterol in a Randomized Trial.

Authors:  M Catherine Prater; Alexis R Scheurell; Chad M Paton; Jamie A Cooper
Journal:  J Nutr       Date:  2022-09-06       Impact factor: 4.687

7.  Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin.

Authors:  Brian Lu; Laura Sun; Manuel Seraydarian; Thomas J Hoffmann; Marisa W Medina; Neil Risch; Carlos Iribarren; Ronald M Krauss; Akinyemi Oni-Orisan
Journal:  Clin Pharmacol Ther       Date:  2021-07-23       Impact factor: 6.903

8.  The impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quantitative change.

Authors:  Neil Risch; Thomas J Hoffmann; Akinyemi Oni-Orisan; Tanushree Haldar; Dilrini K Ranatunga; Marisa W Medina; Catherine Schaefer; Ronald M Krauss; Carlos Iribarren
Journal:  NPJ Genom Med       Date:  2020-01-16       Impact factor: 8.617

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.